NPI: 1720040777 · PHILADELPHIA, PA 19106 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 04/05/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 04/05/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 12,811 | $612.75 |
| 2020 | 1,624 | $135K |
| 2021 | 5,066 | $507K |
| 2022 | 1,573 | $157K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 10,126 | 893 | $799K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 4,274 | 239 | $612.75 |
| G0009 | Administration of pneumococcal vaccine | 25 | 24 | $193.83 |
| 82728 | 364 | 324 | $0.00 | |
| A4657 | Syringe, with or without needle, each | 1,125 | 547 | $0.00 |
| 83550 | 416 | 323 | $0.00 | |
| J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) | 21 | 13 | $0.00 |
| J1270 | Injection, doxercalciferol, 1 mcg | 2,422 | 220 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 14 | 14 | $0.00 |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 19 | 17 | $0.00 |
| 90674 | 13 | 13 | $0.00 | |
| 86706 | 13 | 13 | $0.00 | |
| 83970 | 351 | 309 | $0.00 | |
| 85048 | 331 | 317 | $0.00 | |
| 83540 | 416 | 323 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 782 | 214 | $0.00 |
| 85041 | 332 | 318 | $0.00 | |
| 82108 | 30 | 29 | $0.00 |